Serum B-Cell maturation antigen is an independent prognostic marker in previously untreated chronic lymphocytic leukemia.

Autor: Soof CM; OncoTracker Inc., West Hollywood, CA; Oncotherapeutics, West Hollywood, CA., Spektor TM; Oncotherapeutics, West Hollywood, CA., Parikh SA; Division of Hematology, Mayo Clinic, Rochester, MN., Slager SL; Division of Hematology, Mayo Clinic, Rochester, MN; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN., Rabe KG; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN., Call TG; Division of Hematology, Mayo Clinic, Rochester, MN., Kenderian SS; Division of Hematology, Mayo Clinic, Rochester, MN., Ding W; Division of Hematology, Mayo Clinic, Rochester, MN., Muchtar E; Division of Hematology, Mayo Clinic, Rochester, MN., Ghermezi M; Oncotherapeutics, West Hollywood, CA., Kay NE; Division of Hematology, Mayo Clinic, Rochester, MN., Berenson JR; OncoTracker Inc., West Hollywood, CA; Oncotherapeutics, West Hollywood, CA; Institute for Myeloma and Bone Cancer Research, West Hollywood, CA. Electronic address: jberenson@berensoncancercenter.com.

Publikováno v: Experimental hematology [Exp Hematol] 2022 Jul; Vol. 111, pp. 32-40. Date of Electronic Publication: 2022 May 05.

Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells.

Autor: Chen H; Institute for Myeloma & Bone Cancer Research, West Hollywood, CA, United States., Li M; Institute for Myeloma & Bone Cancer Research, West Hollywood, CA, United States., Xu N; Institute for Myeloma & Bone Cancer Research, West Hollywood, CA, United States., Ng N; Institute for Myeloma & Bone Cancer Research, West Hollywood, CA, United States., Sanchez E; Institute for Myeloma & Bone Cancer Research, West Hollywood, CA, United States., Soof CM; Institute for Myeloma & Bone Cancer Research, West Hollywood, CA, United States., Patil S; Institute for Myeloma & Bone Cancer Research, West Hollywood, CA, United States., Udd K; Institute for Myeloma & Bone Cancer Research, West Hollywood, CA, United States., Bujarski S; Institute for Myeloma & Bone Cancer Research, West Hollywood, CA, United States., Cao J; Institute for Myeloma & Bone Cancer Research, West Hollywood, CA, United States., Hekmati T; Institute for Myeloma & Bone Cancer Research, West Hollywood, CA, United States., Ghermezi M; Oncotherapeutics Inc., West Hollywood, CA, United States., Zhou M; Institute for Myeloma & Bone Cancer Research, West Hollywood, CA, United States., Wang EY; Institute for Myeloma & Bone Cancer Research, West Hollywood, CA, United States., Tanenbaum EJ; Institute for Myeloma & Bone Cancer Research, West Hollywood, CA, United States., Zahab B; Institute for Myeloma & Bone Cancer Research, West Hollywood, CA, United States., Schlossberg R; Institute for Myeloma & Bone Cancer Research, West Hollywood, CA, United States., Yashar MA; Institute for Myeloma & Bone Cancer Research, West Hollywood, CA, United States., Wang CS; Institute for Myeloma & Bone Cancer Research, West Hollywood, CA, United States., Tang GY; Institute for Myeloma & Bone Cancer Research, West Hollywood, CA, United States., Spektor TM; Oncotherapeutics Inc., West Hollywood, CA, United States., Berenson JR; Institute for Myeloma & Bone Cancer Research, West Hollywood, CA, United States; Oncotherapeutics Inc., West Hollywood, CA, United States. Electronic address: jberenson@imbcr.org.

Publikováno v: Leukemia research [Leuk Res] 2019 Jun; Vol. 81, pp. 62-66. Date of Electronic Publication: 2019 Apr 18.

The clinical significance of B-cell maturation antigen as a therapeutic target and biomarker.

Autor: Sanchez E; a Institute for Myeloma and Bone Cancer Research (IMBCR) , West Hollywood , CA , USA., Tanenbaum EJ; a Institute for Myeloma and Bone Cancer Research (IMBCR) , West Hollywood , CA , USA., Patil S; a Institute for Myeloma and Bone Cancer Research (IMBCR) , West Hollywood , CA , USA., Li M; a Institute for Myeloma and Bone Cancer Research (IMBCR) , West Hollywood , CA , USA., Soof CM; a Institute for Myeloma and Bone Cancer Research (IMBCR) , West Hollywood , CA , USA., Vidisheva A; b University of Arizona College of Medicine - Tucson , Tucson , AZ , USA., Waterman GN; c Keck School of Medicine, University of Southern California - Los Angeles , Los Angeles , CA , USA., Hekmati T; a Institute for Myeloma and Bone Cancer Research (IMBCR) , West Hollywood , CA , USA., Tang G; a Institute for Myeloma and Bone Cancer Research (IMBCR) , West Hollywood , CA , USA., Wang CS; a Institute for Myeloma and Bone Cancer Research (IMBCR) , West Hollywood , CA , USA., Chen H; a Institute for Myeloma and Bone Cancer Research (IMBCR) , West Hollywood , CA , USA., Berenson J; a Institute for Myeloma and Bone Cancer Research (IMBCR) , West Hollywood , CA , USA.

Publikováno v: Expert review of molecular diagnostics [Expert Rev Mol Diagn] 2018 Apr; Vol. 18 (4), pp. 319-329. Date of Electronic Publication: 2018 Mar 07.

A Phase I Trial Evaluating the Addition of Lenalidomide to Patients with Relapsed/Refractory Multiple Myeloma Progressing on Ruxolitinib and Methylprednisolone.

Autor: Berenson JR; Institute for Myeloma & Bone Cancer Research, West Hollywood, CA, USA. jberenson@berensoncancercenter.com.; ONCOtherapeutics, 9201 Sunset Boulevard Suite 300, West Hollywood, CA, 90069, USA. jberenson@berensoncancercenter.com.; Berenson Cancer Center, West Hollywood, CA, USA. jberenson@berensoncancercenter.com., Limon A; ONCOtherapeutics, 9201 Sunset Boulevard Suite 300, West Hollywood, CA, 90069, USA., Rice S; ONCOtherapeutics, 9201 Sunset Boulevard Suite 300, West Hollywood, CA, 90069, USA., Safaie T; ONCOtherapeutics, 9201 Sunset Boulevard Suite 300, West Hollywood, CA, 90069, USA., Boccia R; Center for Cancer and Blood Disorders, Bethesda, MD, USA., Yang H; The Oncology Institute of Hope and Innovation, Alhambra, CA, USA., Moezi M; Cancer Specialists of North Florida, Fleming Island, FL, USA., Lim S; Cedars Sinai Samuel Oschin Cancer Center, Los Angeles, CA, USA., Schwartz G; Berenson Cancer Center, West Hollywood, CA, USA., Eshaghian S; Los Angeles Cancer Network, Los Angeles, CA, USA., Brobeck M; ONCOtherapeutics, 9201 Sunset Boulevard Suite 300, West Hollywood, CA, 90069, USA., Swift R; Berenson Cancer Center, West Hollywood, CA, USA., Eades BM; Berenson Cancer Center, West Hollywood, CA, USA., Bujarski S; Berenson Cancer Center, West Hollywood, CA, USA., Sebhat Y; Berenson Cancer Center, West Hollywood, CA, USA., Ray R; Berenson Cancer Center, West Hollywood, CA, USA., Kim S; ONCOtherapeutics, 9201 Sunset Boulevard Suite 300, West Hollywood, CA, 90069, USA., Del Dosso A; ONCOtherapeutics, 9201 Sunset Boulevard Suite 300, West Hollywood, CA, 90069, USA., Vescio R; Cedars Sinai Samuel Oschin Cancer Center, Los Angeles, CA, USA.

Publikováno v: Targeted oncology [Target Oncol] 2024 May; Vol. 19 (3), pp. 343-357. Date of Electronic Publication: 2024 Apr 20.

CAR-T cell therapy in Multiple Myeloma: current status and future challenges.

Autor: Swan, Dawn, Madduri, Deepu, Hocking, Jay

Publikováno v: Blood Cancer Journal; 11/26/2024, Vol. 14 Issue 1, p1-16, 16p